Develops therapies specializing in aging disorders and increasing human longevity. Founded in 2016 by Dr. Greg Bailey and Jim Mellon. Valued at ~$500M with ~$219M raised. Lead candidate is an oral PAI-1 inhibitor for fibrosis in Phase 1 trials. *Catalogued by Claude* On this page you can view the company profile, browse linked jobs, products, posts, and ventures, inspect verification and contact details, follow related identity links.